RMD
ResMed Inc. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth +5.6% ·
share flow +0.7% ·
net new positions +5.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 157 | +2 | 75.82M | $14.78B | +7 | −6 |
| Q1 2026 | 159 | +3 | 74.11M | $16.62B | +5 | −3 |
| Q4 2025 | 155 | -2 | 83.70M | $20.16B | +1 | −2 |
| Q3 2025 | 21 | 0 | 49.43M | $13.53B | n/a | −1 |
| Q2 2025 | 19 | +1 | 44.83M | $11.56B | +1 | n/a |
| Q1 2025 | 15 | -1 | 12.96M | $2.90B | n/a | −1 |
| Q4 2024 | 16 | -2 | 12.69M | $2.90B | n/a | −2 |
| Q3 2024 | 17 | +2 | 6.96M | $1.70B | +2 | n/a |
| Q2 2024 | 15 | n/a | 5.93M | $1.13B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 18.75M | n/a | $4.84B | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 12.44M | n/a | $3.21B | 0.1% | n/c | 1 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (passive) | 6.62M | +1.0% | $1.71B | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 4.22M | +2.4% | $1.08B | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 1.19M | +105.9% | $306.45M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 367.40K | +853.5% | $94.79M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Fidelity (FMR) ✦ | 344.80K | n/a | $88.96M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | T. Rowe Price ✦ | 343.14K | +0.4% | $88.53M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 186.55K | -53.6% | $47.81M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 10 | Renaissance Technologies ✦ | 103.00K | +90.7% | $26.57M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Millennium Management ✦ | 91.40K | +137.2% | $23.58M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 77.07K | +32.4% | $19.88M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Fisher Asset Management ✦ | 46.77K | +0.7% | $12.07M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 27.78K | +57.5% | $7.17M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 15 | Marshall Wace ✦ | 12.57K | -97.7% | $3.24M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 11.67K | -38.4% | $3.01M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 5.25K | -95.6% | $1.36M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 2.10K | -91.5% | $541,542 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 1.51K | New | $388,806 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $388,806 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 932 holders, 96.37M shares, $21.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 4.99K sh · $1.13M
Officer, Director · 4.99K sh · $1.11M
Director · 970 sh · $227,688
Officer, Director · 4.99K sh · $1.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology